Fibroblast growth factor 23 and its receptors

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Fibroblast growth factor 23 (FGF23) is a circulating factor that plays critical roles in phosphate and vitamin D metabolism, as evidenced by the fact that FGF23 missense mutations cause autosomal dominant hypophosphatemic rickets (ADHR). Autosomal dominant hypophosphatemic rickets is characterized by hypophosphatemia with inappropriately normal 1,25-dihydroxyvitamin D concentrations, as well as bone pain, fracture and rickets. This phenotype parallels that of patients with tumor induced osteomalacia (TIO), X-linked hypophosphatemic rickets (XLH), and fibrous dysplasia (FD), in whom elevated serum FGF23 levels are often observed. The fibroblast growth factor receptors (FGFR1-4) play key roles in skeletal development, as well as in normal metabolic processes. Several FGFR isoforms that potentially mediate the activity of FGF23 have been implicated. In the short term, these findings will lead to further understanding of FGF23 function, and potentially in the long term, to targeted therapies in disorders of hypo- and hyperphosphatemia that involve FGF23.

Original languageEnglish (US)
Pages (from-to)308-312
Number of pages5
JournalTherapeutic Apheresis and Dialysis
Volume9
Issue number4
DOIs
StatePublished - Aug 2005

Keywords

  • Fibroblast growth factor-23
  • Fibrous dysplasia
  • Hypophosphatemia
  • Rickets
  • Tumor induced osteomalacia

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Fingerprint Dive into the research topics of 'Fibroblast growth factor 23 and its receptors'. Together they form a unique fingerprint.

  • Cite this